Focus Contact

LeafBio, Inc. is the commercialization arm of Mapp Biopharmaceutical.


February 6, 2015 at 8:30 AM - LeafBio, Inc. submitted an Investigational New Drug (IND) application for clinical evaluation of ZMapp™ to the Food and Drug Administration (FDA) on February 3, 2015.

February 27, 2015 at 8:30 AM - Mapp Bio Clinical Trials Press Release

Monoclonal Antibody-based Filovirus Therapeutic Licensed to Leaf Biopharmaceutical July 15, 2014

Experimental Ebola Treatment Protects Some Primates Even After Disease Symptoms Appear August 21, 2013

ZMapp™ Information Sheet

ZMapp™ Frequently Asked Questions